KRAS and neoplasm: In the KRAS G12D LS513 colorectal cancer model, SJ-C1044 was administered orally at 20, 40, or 80 mg/kg, once a day (QD), and significant tumor growth suppression was observed in a dose-dependent manner (Figure 3B).